San Francisco startup Structure Therapeutics can be working on an oral, at the time-every day GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s expectations in June each time a mid-phase study showed regular weight loss of close to 6% and it programs to begin An additional